UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

 

001-35342

Commission File Number

 

 

LUMOS PHARMA, INC.

(Exact name of registrant as specified in its charter)

 

 

4200 Marathon Blvd., Suite 200

Austin, Texas 78756

(512) 215-2630

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock, $0.01 par value per share

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)   x
Rule 12g-4(a)(2)   ¨
Rule 12h-3(b)(1)(i)   x
Rule 12h-3(b)(1)(ii)   ¨
Rule 15d-6   ¨
Rule 15d-22(b)   ¨

 

Approximate number of holders of record as of the certification or notice date: One

 

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Lumos Pharma, Inc. has caused this certification/notice to be signed and filed on its behalf by the undersigned duly authorized person.

 

Date: December 23, 2024 LUMOS PHARMA, INC.
     
  By:

/s/ Richard J. Hawkins

    Richard J. Hawkins
    Chief Executive Officer

 

 

 

Lumos Pharma (NASDAQ:LUMO)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Lumos Pharma Charts.
Lumos Pharma (NASDAQ:LUMO)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Lumos Pharma Charts.